Dozens Of Generic Makers And Pharmacies Won’t Face Lawsuits Over Zantac And Cancer Risks
A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in sprawling litigation over allegations that the Zantac heartburn pill may contain a carcinogen, although brand-name drug makers will continue to face more than 1,400 lawsuits over the issue. The ruling is the latest chapter in an ongoing saga of the widely used heartburn medicine, which is also known as ranitidine.